Clinical implications of chronic therapy for GERD. Preface.

[1]  M. Abouzari,et al.  Pyloric Injection of Botulinum Toxin for the Treatment of Refractory GERD Accompanied with Gastroparesis: A Preliminary Report , 2008, Digestive Diseases and Sciences.

[2]  A. Hanlon,et al.  Botulinum Toxin A for the Treatment of Delayed Gastric Emptying , 2008, The American Journal of Gastroenterology.

[3]  R. Fass,et al.  Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn , 2007, Alimentary pharmacology & therapeutics.

[4]  D. Sifrim,et al.  Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus , 2007, Gut.

[5]  W. Chey,et al.  Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome , 2007, Alimentary pharmacology & therapeutics.

[6]  M. Noar,et al.  Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure. , 2007, Gastrointestinal endoscopy.

[7]  A. Reymunde,et al.  Long-term results of radiofrequency energy delivery for the treatment of GERD: sustained improvements in symptoms, quality of life, and drug use at 4-year follow-up. , 2007, Gastrointestinal endoscopy.

[8]  D. O. Castell,et al.  Combined multichannel intraluminal impedance–pH monitoring to select patients with persistent gastro‐oesophageal reflux for laparoscopic Nissen fundoplication , 2006, The British journal of surgery.

[9]  J. Inadomi,et al.  Sub‐optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro‐oesophageal reflux disease , 2006, Alimentary pharmacology & therapeutics.

[10]  S. Shay,et al.  Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring , 2006, Gut.

[11]  A. Hila,et al.  Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. , 2005, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[12]  R. Fass,et al.  Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next? , 2005, Alimentary pharmacology & therapeutics.

[13]  A. Fendrick,et al.  Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs , 2003, American Journal of Gastroenterology.

[14]  M. Harnish,et al.  The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity , 2003, Alimentary pharmacology & therapeutics.

[15]  D. Castell,et al.  Baclofen decreases acid and non‐acid post‐prandial gastro‐oesophageal reflux measured by combined multichannel intraluminal impedance and pH , 2003, Alimentary pharmacology & therapeutics.

[16]  J. Murray,et al.  An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy , 2002, Alimentary pharmacology & therapeutics.

[17]  J. Richter,et al.  Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. , 2002, Gastroenterology.

[18]  J. Dent,et al.  Control of transient lower oesophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease , 2002, Gut.

[19]  Fouad,et al.  Oesophageal motility defects associated with nocturnal gastro‐oesophageal reflux on proton pump inhibitors , 1999, Alimentary pharmacology & therapeutics.

[20]  K. Mine,et al.  Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. , 1999, Journal of clinical gastroenterology.

[21]  Hatlebakk,et al.  Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily , 1998, Alimentary pharmacology & therapeutics.

[22]  D. Castell,et al.  Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. , 1998, Gastroenterology.

[23]  D. Castell,et al.  Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors , 1998, American Journal of Gastroenterology.

[24]  J. Dent,et al.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole. , 1988, Gastroenterology.

[25]  R. Clouse,et al.  Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. , 1987, Gastroenterology.

[26]  R. Sampliner,et al.  Barrett’s Oesophagus , 2012, Drugs.

[27]  Southern Arizona.  Non-erosive reflux disease (NERD) — acid reflux and symptom patterns , 2003 .

[28]  J. Dent,et al.  Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. , 2000, Gastroenterology.

[29]  I. Wiklund,et al.  Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. , 1998, European journal of gastroenterology & hepatology.